Evidence map›Paper›PMID 39688776›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2025

Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study.

Catherine B Johannes, Ryan Ziemiecki, Manel Pladevall-Vila, Natalie Ebert, Csaba P Kovesdy, Reimar W Thomsen, Brenda N Baak, Aníbal García-Sempere, Hiroshi Kanegae, Craig I Coleman and 21 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05526157. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05526157 completed

FINErenone druG Utilization Study and Assessment of Temporal Changes Following Availability of Different Treatment Options in Patients With Chronic Kidney Disease and Type 2 Diabetes

Ran2022Enrolled50,000Registered outcomes5Posted comparisons0ConditionsChronic Kidney Disease, Type 2 Diabetes MellitusArmsFinerenone (Kerendia, BAY 948862), Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Non-steroidal mineral corticoid receptor antagonists (nsMRA), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Steroidal mineral corticoid receptor antagonists (sMRA)
Open the trial in the graph
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Catherine B JohannesRTI Health Solutions, Waltham, MA, USA.
Ryan ZiemieckiRTI Health Solutions, Research Triangle Park, NC, USA.
Manel Pladevall-VilaRTI Health Solutions, Barcelona, Spain.
Natalie EbertCharité-Universitätsmedizin Berlin, Berlin, Germany.
Csaba P KovesdyDivision of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Reimar W ThomsenDepartment of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Brenda N BaakPHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.
Aníbal García-SempereValencia Health System Integrated Database, Health Services Research Unit, Valencia, Spain.
Hiroshi KanegaeGenki Plaza Medical Centre for Health Care, Tokyo, Japan.
Craig I ColemanUniversity of Connecticut School of Pharmacy, Storrs, CT, USA.
Michael WalshDivision of Nephrology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Ina Trolle AndersenDepartment of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Clara Rodríguez BernalValencia Health System Integrated Database, Health Services Research Unit, Valencia, Spain.
Celia Robles CabaniñasValencia Health System Integrated Database, Health Services Research Unit, Valencia, Spain.
Christian Fynbo ChristiansenDepartment of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Alfredo E FarjatBayer AG, Berlin, Germany.
Alain GayBayer AG, Berlin, Germany.
Patrick GeeNational Kidney Foundation Advocacy, Richmond, VA, USA.
Ron M C HeringsPHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.
Isabel HurtadoValencia Health System Integrated Database, Health Services Research Unit, Valencia, Spain.
Naoki KashiharaDepartment of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Japan.
Frederik Pagh Bredahl KristensenDepartment of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Fangfang LiuBayer AG, Berlin, Germany.
Suguru OkamiBayer AG, Berlin, Germany.
Jetty A OverbeekPHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.
Fernie J A Penning-van BeestPHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.
Satoshi YamashitaBayer AG, Berlin, Germany.
Yuichiro YanoNCD Epidemiology Research Center, Shiga University of Medical Science, Shiga, Japan.
J Bradley LaytonRTI Health Solutions, Research Triangle Park, NC, USA.
David VizcayaBayer AG, Berlin, Germany.
Nikolaus G OberprielerBayer AG, Berlin, Germany. niki.oberprieler@bayer.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe clinical landscape for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) is rapidly evolving. As part of the FOUNTAIN platform (NCT05526157; EUPAS48148), we described and compared cohorts of adult patients with CKD and T2D initiating a sodium-glucose cotransporter 2 inhibitor (SGLT2i) before the launch of finerenone in Europe, Japan, and the United States (US).

methodsThis was a multinational, multi-cohort study of patients with T2D in five data sources: the Danish National Health Registers (DNHR) (Denmark), PHARMO Data Network (The Netherlands), Valencia Health System Integrated Database (VID) (Spain), Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex) (Japan), and Optum's de-identified Clinformatics

resultsThe final cohorts included 21,739 patients in DNHR, 381 in PHARMO, 31,785 in VID, 1157 in J-CKD-DB-Ex, and 56,219 in CDM. Across data sources, approximately 41-70% had CKD stage 1 or 2 at baseline; severe CKD (stage 4) was uncommon (1.6-6.7%). The median duration of SGLT2i therapy ranged from 7.5 months in PHARMO to 17.0 months in VID. At least 50% of patients were currently receiving SGLT2i treatment at 1 year after initiation.

conclusionsAt a 1-year follow-up, at least half of the patients with CKD and T2D were receiving SGLT2i treatment across the data sources. In patients initiating SGLT2i, treatment options for T2D and CKD were heterogeneous and dynamic within and among data sources.

Indexed as

Chronic kidney diseaseCKDDanish National Health Registers (DNHR)Drug utilizationFOUNTAINJapan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex)Optum’s de-identified Clinformatics® Data Mart Database (CDM)PHARMO Data NetworkSGLT2 inhibitorT2DType 2 diabetesValencia Health System Integrated Database (VID)

Identifiers

PMID39688776
PMCPMC11794911

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.